Management Of Hyperlipidemia
Once purchased the link emailed to you is valid for 60 days. If you do not complete the course within 60 days call the FPA office and we will resend the link to complete the course.
FPA Correspondence Course
Approved for Florida Consultant Recertification
3 Contact Hours or 0.3 CEU's
EDUCATIONAL NEEDS ASSESSMENT
Hyperlipidemia is abnormally elevated levels of any or all lipids or lipoproteins in the blood. It is the most common form of dyslipidemia.
Dyslipidemias can affect any lipid parameter, including LDL cholesterol,
levels, HDL cholesterol levels, triglycerides, or a combination of these lipids. There are many factors that can cause dyslipidemia – ranging from inherited disorders to your lifestyle.
According to the Centers for Disease Control and Prevention (CDC), more than 12% of adults age 20 and older had total cholesterol higher than 240 mg/dL, and more than 18% had high-density lipoprotein (HDL, or “good”) cholesterol levels less than 40 mg/dL.
Slightly more than half of the U.S. adults (55%, or 43 million) who could benefit from cholesterol medicine are currently taking it.
95 million U.S. adults age 20 or older have total cholesterol levels
higher than 200 mg/dL. Nearly 29 million adult Americans have total cholesterol levels higher than 240 mg/dL.
7% of U.S. children and adolescents ages 6 to 19 have high total cholesterol. High cholesterol has no symptoms, so many people do not
know that their cholesterol is too high. A simple blood test can check cholesterol levels. Having high blood cholesterol raises the risk for heart disease, the leading cause of death, and for stroke, the fifth leading
cause of death.
The health care costs associated with hyperlipidemia and its complications are growing at an alarming rate. The American
College of Cardiology–American Heart Association (ACC-AHA) has released the 2018 guidelines on the treatment of high cholesterol which will give clinicians the tools to provide desirable goals and targets for patients.
At the completion of this home study activity, pharmacists will be able to: Explain the epidemiology of hyperlipidemia; Describe the clinical presentation of lipids; Explain the normal physiology of lipids; Describe the pathogenesis of atherosclerosis; Identify causes of dyslipidemia; Compare and contrast the various pharmacological agents used to treat hyperlipidemia; Select appropriate therapy for patients with high cholesterol; Identify lifestyle modifications that are vital to the prevention and management of hyperlipidemia; Identify the role of the pharmacist in the management of hyperlipidemia.
Pharmacy Association is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education. Three (3) contact hours are available upon completion of the posttest questions and evaluation form. You
must pass the exam with a score of 70% or better.
This is an ACPE knowledge-based activity.
Initial Release Date: May 1, 2019. Expiration Date: May
1, 2022. UAN: 0165-0000-19-053-H01-P. Florida Board of Pharmacy approval number 20-653823